GLP-1s: Study Share

My_Pal said:
Nice! I am in my fifth week (upped to 5mg from 2.5mg).
Click to expand...

How is it going? Side effects? I found semaglutide to be great with no side effects. Considering maybe doing a week on the starter dose and getting right into it since I didn't have any issues at all from semaglutide. How effective is it?
 
Alex said:
How is it going? Side effects? I found semaglutide to be great with no side effects. Considering maybe doing a week on the starter dose and getting right into it since I didn't have any issues at all from semaglutide. How effective is it?
Click to expand...

I think its been amazing and has really changed how I see food. The first couple of days after the 5mg dose made me pretty nauseous, but its fading quickly. I know its temporary, so no big deal. The 2.5mg did the same. Its supposed to take a month for the drug to fully work and "teach" the GIP and GLP1 receptors. After that...
 
I am just beginning semaglutide -- any advice on dosage? When to increase, etc? Just trying to get some info before I start.
 
I'm curious - is anyone experiencing side effects from their medication? I'm trying to be prepared for anything.
 
The anti-inflammatory effect might be doing a lot of the liver protection work. Lowering that systemic inflammation decreases cytokine levels, which helps slow down the fatty liver progression toward fibrosis or cirrhosis.
 
Responded to an ad for an oral GLP drug trial in town. Started researching gray market products. At intake the study was full. Got hard-sold on a different trial I don't recall but it involved liver biopsy. Hard pass. Lab was filthy - uncomfortable even getting blood work so declined further tests.
 
GI side effects and appetite suppression don't track the same — that's what most people miss. Nausea easing at higher doses means your gut adapted to slower stomach emptying, good long-term. But food noise isn't dose-linear — some people peak at 0.5mg, others need 1.7 or 2.4mg.
 
once you stop and restart it takes longer and higher dose before you see effects again. be patient. keep the faith. good luck.
 
The NYT coverage reflects how fast the clinical picture is expanding - new applications (cardiovascular, addiction, neurological) are getting mainstream publication because the trial data is now large enough to be newsworthy. The formatting issue with gift articles is usually the NYT paywall interaction; direct link share works better than copy-paste for most readers.
 
The ADHD/GLP-1 intersection has early data - the dopaminergic pathway effects that GLP-1s produce overlap with attention regulation circuits. Not a core finding yet but the reward circuit connection makes it plausible.
 
You must log in or register to reply here.
Back
Top